

## Statement of Unaudited Results for the Quarter and Half year ended 30th September, 2012

(₹ in Lacs)

STAND ALONE RESULTS						Particulars	CONSOLIDATED RESULTS					
Quarter Ended			Half Year Ended		Year Ended		Quarter Ended			Half Year Ended		Year Ended
Sep 30	Jun 30	Sep 30	Sep 30	Sep 30	Mar 31		Sep 30	Jun 30	Sep 30	Sep 30	Sep 30	Mar 31
(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
2012	2012	2011	2012	2011	2012	2012	2012	2011	2012	2011	2012	
<b>PART I</b>												
<b>Income from operations</b>												
73986	73682	63137	147668	124627	261764	(a) Net sales/Income from operations (Net of excise duty)	121973	123589	105047	245562	199234	425395
483	575	469	1058	945	2343	(b) Other Operating Income	522	441	403	963	1125	4918
<b>74469</b>	<b>74257</b>	<b>63606</b>	<b>148726</b>	<b>125572</b>	<b>264107</b>	<b>Total income from operations (net)</b>	<b>122495</b>	<b>124030</b>	<b>105450</b>	<b>246525</b>	<b>200359</b>	<b>430313</b>
<b>Expenses</b>												
37471	35435	29893	72906	58348	123995	a) Cost of materials consumed	43854	43572	36657	87426	70235	149469
4944	4727	6630	9671	12336	24368	b) Purchase of traded goods	7485	7902	7871	15387	13621	30534
(2613)	(1718)	(2467)	(4331)	(4684)	(9326)	c) Change in inventories of finished goods, work-in-progress and traded goods	(5448)	(4411)	(5274)	(9859)	(8438)	(18851)
8113	8369	5349	16482	10893	26976	d) Power & fuel	8548	8872	5822	17420	11823	28511
6088	5608	5090	11696	9768	20723	e) Employee benefits expenses	24400	23143	20603	47543	39579	83637
3686	3607	2921	7293	5689	13200	f) Depreciation and amortization expenses	6203	5906	5080	12109	10057	22065
8133	9785	7991	17918	15353	36209	g) Other expenses	17630	17586	15881	35216	31004	69239
<b>8647</b>	<b>8444</b>	<b>8199</b>	<b>17091</b>	<b>17869</b>	<b>27962</b>	<b>Profit/(Loss) from operations before other income, finance cost and exceptional items</b>	<b>19823</b>	<b>21460</b>	<b>18810</b>	<b>41283</b>	<b>32478</b>	<b>65709</b>
295	174	229	469	464	894	Other Income	346	308	340	654	707	1529
<b>8942</b>	<b>8618</b>	<b>8428</b>	<b>17560</b>	<b>18333</b>	<b>28856</b>	<b>Profit/(Loss) from ordinary activities before finance costs &amp; exceptional items</b>	<b>20169</b>	<b>21768</b>	<b>19150</b>	<b>41937</b>	<b>33185</b>	<b>67238</b>
4323	4505	3658	8828	6661	15442	Finance costs	5740	5934	5053	11674	9415	20959
<b>4619</b>	<b>4113</b>	<b>4770</b>	<b>8732</b>	<b>11672</b>	<b>13414</b>	<b>Profit/(Loss) from ordinary activities after finance costs but before exceptional items</b>	<b>14429</b>	<b>15834</b>	<b>14097</b>	<b>30263</b>	<b>23770</b>	<b>46279</b>
(4922)	10424	4160	5502	4428	18008	Exceptional items	(4946)	10424	4260	5478	4678	34868
<b>9541</b>	<b>(6311)</b>	<b>610</b>	<b>3230</b>	<b>7244</b>	<b>(4594)</b>	<b>Profit/(Loss) from ordinary activities before tax</b>	<b>19375</b>	<b>5410</b>	<b>9837</b>	<b>24785</b>	<b>19092</b>	<b>11411</b>
1181	1049	110	2230	1355	3497	Tax expense (Net)	3528	3887	930	7415	2446	6842
<b>8360</b>	<b>(7360)</b>	<b>500</b>	<b>1000</b>	<b>5889</b>	<b>(8091)</b>	<b>Net Profit/(Loss) from ordinary activities after tax</b>	<b>15847</b>	<b>1523</b>	<b>8907</b>	<b>17370</b>	<b>16646</b>	<b>4569</b>
-	-	-	-	-	-	Extraordinary items (net of tax expenses)	-	-	-	-	-	-
<b>8360</b>	<b>(7360)</b>	<b>500</b>	<b>1000</b>	<b>5889</b>	<b>(8091)</b>	<b>Net Profit/(Loss) for the period</b>	<b>15847</b>	<b>1523</b>	<b>8907</b>	<b>17370</b>	<b>16646</b>	<b>4569</b>
-	-	-	-	-	-	Share of Profit/(Loss) of Associate Company	-	-	-	-	-	-
-	-	-	-	-	-	Minority Interest	647	1022	971	1669	998	3113
<b>8360</b>	<b>(7360)</b>	<b>500</b>	<b>1000</b>	<b>5889</b>	<b>(8091)</b>	<b>Net Profit/(Loss) after taxes, minority interest and share of profit/loss of associates</b>	<b>15200</b>	<b>501</b>	<b>7936</b>	<b>15701</b>	<b>15648</b>	<b>1456</b>
1593	1593	1593	1593	1593	1593	Paid-up equity share capital (Face value per share ₹ 1)	1593	1593	1593	1593	1593	1593
-	-	-	-	-	-	Reserves (excluding revaluation reserve)	-	-	-	-	-	231384
5.25	(4.62)	0.31	0.63	3.69	(5.08)	Earnings per share before and after extraordinary items (Not annualized)	9.54	0.31	4.98	9.85	9.82	0.91
5.25	(4.62)	0.31	0.63	3.69	(5.08)	<b>Basic (₹)</b>	<b>9.54</b>	<b>0.31</b>	<b>4.98</b>	<b>9.85</b>	<b>9.82</b>	<b>0.91</b>
-	-	-	-	-	-	<b>Diluted (₹)</b>	<b>9.54</b>	<b>0.31</b>	<b>4.98</b>	<b>9.85</b>	<b>9.82</b>	<b>0.91</b>
<b>PART II</b>												
<b>PARTICULARS OF SHAREHOLDING</b>												
Public shareholding												
81166083	81166083	81344677	81166083	81344677	81166083	- Number of shares (₹ 1 each)	81166083	81166083	81344677	81166083	81344677	81166083
50.96	50.96	51.07	50.96	51.07	50.96	- Percentage of shareholding	50.96	50.96	51.07	50.96	51.07	50.96
Promoters and promoter group Shareholding												
<b>a) Pledged/Encumbered</b>												
3374000	3374000	6552333	3374000	6552333	3374000	- Number of shares	3374000	3374000	6552333	3374000	6552333	3374000
4.32	4.32	8.41	4.32	8.41	4.32	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	4.32	4.32	8.41	4.32	8.41	4.32
2.12	2.12	4.11	2.12	4.11	2.12	- Percentage of shares (as a % of the total share capital of the company)	2.12	2.12	4.11	2.12	4.11	2.12
<b>b) Non-Encumbered</b>												
74741056	74741056	71384129	74741056	71384129	74741056	- Number of shares	74741056	74741056	71384129	74741056	71384129	74741056
95.68	95.68	91.59	95.68	91.59	95.68	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	95.68	95.68	91.59	95.68	91.59	95.68
46.92	46.92	44.82	46.92	44.82	46.92	- Percentage of shares (as a % of the total share capital of the company)	46.92	46.92	44.82	46.92	44.82	46.92
<b>Investor Complaints</b>												
Pending at the beginning of the quarter							Nil					
Received during the quarter							9					
Disposed of during the quarter							9					
Remaining unresolved at the end of the quarter							Nil					

Segment wise Revenue, Results and Capital Employed (under Clause 41 of the Listing Agreement)												
STAND ALONE RESULTS						Particulars	CONSOLIDATED RESULTS					
Quarter Ended			Half Year Ended		Year Ended		Quarter Ended			Half Year Ended		Year Ended
Sep 30	Jun 30	Sep 30	Sep 30	Sep 30	Mar 31		Sep 30	Jun 30	Sep 30	Sep 30	Sep 30	Mar 31
(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
2012	2012	2011	2012	2011	2012	2012	2012	2011	2012	2011	2012	
<b>Segment revenue</b>												
18717	17241	13104	35958	24409	56811	a. Pharmaceuticals	64954	64124	55338	129078	99363	220131
55820	57084	50586	112904	101342	207602	b. Life Sciences Ingredients	57609	59974	50196	117583	101175	210488
<b>74537</b>	<b>74325</b>	<b>63690</b>	<b>148862</b>	<b>125751</b>	<b>264413</b>	<b>Total</b>	<b>122563</b>	<b>124098</b>	<b>105534</b>	<b>246661</b>	<b>200538</b>	<b>430619</b>
68	68	84	136	179	306	Less : Inter segment revenue	68	68	84	136	179	306
<b>74469</b>	<b>74257</b>	<b>63606</b>	<b>148726</b>	<b>125572</b>	<b>264107</b>	<b>Net Sales/Income from operations</b>	<b>122495</b>	<b>124030</b>	<b>105450</b>	<b>246525</b>	<b>200359</b>	<b>430313</b>
18717	17241	13104	35958	24409	56811	a. Pharmaceuticals	64954	64124	55338	129078	99363	220131
55752	57016	50502	112768	101163	207296	b. Life Sciences Ingredients	57541	59906	50112	117447	100996	210182
<b>74469</b>	<b>74257</b>	<b>63606</b>	<b>148726</b>	<b>125572</b>	<b>264107</b>	<b>Total</b>	<b>122495</b>	<b>124030</b>	<b>105450</b>	<b>246525</b>	<b>200359</b>	<b>430313</b>
<b>Segment results (profit+/- loss-) before tax and interest from each segment)</b>												
3435	4313	2278	7748	3462	10032	a. Pharmaceuticals	13627	16431	12820	30058	17890	47088
4366	7862	7855	12228	18060	25612	b. Life Sciences Ingredients	5350	8760	7902	14110	18241	26302
<b>7801</b>	<b>12175</b>	<b>10133</b>	<b>19976</b>	<b>21522</b>	<b>35644</b>	<b>Total</b>	<b>18977</b>	<b>25191</b>	<b>20722</b>	<b>44168</b>	<b>36131</b>	<b>73390</b>
4323	4505	3658	8828	6661	15442	Less : i Interest (Finance costs)	5740	5934	5053	11674	9415	20959
(5768)	14155	6094	8387	8081	25690	ii. Other un-allocable expenditure (including exceptional items)	(5792)	14155	6172	8363	8331	42549
(295)	(174)	(229)	(469)	(464)	(894)	iii. Un-allocable Income (including exceptional items)	(346)	(308)	(340)	(654)	(707)	(1529)
<b>9541</b>	<b>(6311)</b>	<b>610</b>	<b>3230</b>	<b>7244</b>	<b>(4594)</b>	<b>Total Profit/(Loss) before tax</b>	<b>19375</b>	<b>5410</b>	<b>9837</b>	<b>24785</b>	<b>19092</b>	<b>11411</b>
<b>Capital Employed (Segment assets less Segment liabilities)</b>												
98637	94961	88680	98637	88680	90475	a. Pharmaceuticals	449107	450398	411173	449107	411173	417359
165136	167253	154579	165136	154579	162059	b. Life Sciences Ingredients	184195	183674	166378	184195	166378	174624
<b>263773</b>	<b>262214</b>	<b>243259</b>	<b>263773</b>	<b>243259</b>	<b>252534</b>	<b>Total capital employed in segment</b>	<b>633302</b>	<b>634072</b>	<b>577551</b>	<b>633302</b>	<b>577551</b>	<b>591983</b>
267460	245702	257380	267460	257380	261221	Add: Un-allocable corporate assets less liabilities	56951	35955	44958	56951	44958	51154
<b>531233</b>	<b>507916</b>	<b>500639</b>	<b>531233</b>	<b>500639</b>	<b>513755</b>	<b>Total capital employed in the Company</b>	<b>690253</b>	<b>670027</b>	<b>622509</b>	<b>690253</b>	<b>622509</b>	<b>643137</b>

## Statement of Assets And Liabilities

(₹ in Lacs)

STAND ALONE		Particulars	CONSOLIDATED	
As at September 30	As at March 31		As at September 30	As at March 31
(Un-audited)	(Audited)		(Un-audited)	(Audited)
2012	2012		2012	2012
<b>EQUITY AND LIABILITIES</b>				
<b>Shareholders' Funds</b>				
1593	1593	a) Share capital	1593	1593
202336	197391	b) Reserves & surplus	260299	231384
-	-	c) Money received against share warrants	-	-
<b>203929</b>	<b>198984</b>	<b>Sub-total- Shareholders' funds</b>	<b>261892</b>	<b>232977</b>
-	-	<b>Share application money pending allotment</b>	-	-
-	-	<b>Minority interest</b>	<b>9103</b>	<b>6895</b>
<b>Non-current liabilities</b>				
242303	242221	a) Long-term borrowings	273906	283992
23372	21141	b) Deferred tax liabilities(Net)	27047	22403
-	-	c) Other long term liabilities	79	76
19080	15689	d) Long-term provisions	20321	16970
<b>284755</b>	<b>279051</b>	<b>Sub-total- Non-current liabilities</b>	<b>321353</b>	<b>323441</b>
<b>Current liabilities</b>				
55919	48473	a) Short-term borrowings	95421	76707
67468	70670	b) Trade payables	81658	83699
19487	18679	c) Other current liabilities	53986	49955
5937	8835			